From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Scancell – Phase I/II trial update and company chat

By Nigel Somerville, The Deputy Sheriff of AIM | Wednesday 3 June 2015


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


As expected, Scancell Holdings (SCLP) delivered an RNS update on its ongoing Phase I/II SCIB-1 drug trials yesterday morning, following its presentation on Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The meeting itself has generated plenty of headlines, with lots of froth about a new cure for cancer from immunotherapy – the space in which Scancell operates: SCIB-1 is a treatment for melanoma. So what of the new data?


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 09:10:55